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Cigarette smoke contains known reproductive
toxicants, and smoking has been associated
with adverse reproductive outcomes in
women such as infertility, subfecundity,
younger age at menopause, and menstrual dis-
orders (Department of Health and Human
Services 2001). Previously (Windham et al.
1999), we reported that smokers had different
menstrual cycle characteristics compared with
nonsmokers; heavy smoking was associated
with shorter and more variable cycle lengths,
with the shortening occurring primarily dur-
ing the follicular phase. There was some sug-
gestion of increased risk of short luteal phase
(< 11 days) and anovulation as well, but the
confidence intervals were quite wide. The
mechanism of these and other reported effects
is not known but may reflect alterations in
hormone function by components of tobacco
smoke, with smoking suggested as having
antiestrogenic effects (Baron et al. 1990).
However, studies examining estrogen and its
metabolites by smoking status have found
somewhat mixed results (Berta et al. 1992;
Key et al. 1996; Longcope and Johnston
1988; Zumoff et al. 1990), perhaps partly due
to limited sampling points.
Hormone function is difﬁcult to study in
non-clinic-based populations because of the
cyclical nature of excretion and day-to-day
variation in premenopausal women. Under
the control of the complex hypothalamic–
pituitary–ovarian (HPO) axis, the steroids
estrogen and progesterone are released from
and reﬂect ovarian activity and in turn modu-
late release of gonadotropins from the pitu-
itary via a negative feedback loop. Rising levels
of the pituitary hormone follicle-stimulating
hormone (FSH) during the luteal to follicular
phase transition between menstrual cycles are
critical for follicle recruitment and develop-
ment in the subsequent cycle (van Santbrink
et al. 1995). Declining levels during the
follicular phase are important for selection of a
dominant follicle and its maturation, and FSH
peaks again around ovulation. FSH level is
considered a marker of ovarian reserve or fertil-
ity (Scott et al. 1989; Scott and Hofman 1995)
and is elevated among women approaching
menopause (Backer et al. 1999; Burger et al.
1995). As such, it may also be useful for iden-
tifying ovarian toxicants (Marcus et al. 1993).
A few studies have suggested that smokers
have higher levels of FSH than do non-
smokers (Backer et al. 1999; Cooper et al.
1995; Cramer et al. 1994). These studies were
based on a single serum sample, collected
either very early in the cycle or with the cycle
timing unknown, and tended to include
older women, some of whom were peri-
menopausal or postmenopausal. Therefore,
the purpose of the present study was to
examine smoking in relation to the patterns of
urinary hormone metabolites throughout the
menstrual cycle in premenopausal women to
determine whether smoking may exert some
of its deleterious effects via an endocrine
mechanism. In particular, we were interested
in measuring whether estrogen excretion
appeared reduced and identifying at what
level such an effect may occur by examining
the pituitary gonadotropin FSH. Ours is the
first study to examine hormone dynamics,
with daily metabolite levels of the steroids
throughout the cycle and FSH during the
luteal–follicular transition, in relation to
smoking that was veriﬁed by bioassay.
Materials and Methods
The data for this investigation are derived
from the Women’s Reproductive Health
Study, a prospective study of menstrual func-
tion and early pregnancy loss conducted
among 403 premenopausal women, whose
data collection and analytic methods have
been described previously (Waller et al. 1998;
Windham et al. 1999) and are summarized
brieﬂy below. The institutional review boards
of both Kaiser Permanente Medical Group
and the California Department of Health
Services approved the protocol, and partici-
pants provided written informed consent.
Women 18–39 years of age enrolled in the
Kaiser Permanente Medical Care Program in
northern California during 1990–1991 were
screened by a short telephone interview to
determine eligibility (based on possibility of
becoming pregnant) and willingness to collect
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Cigarette smoke contains compounds that are suspected to cause reproductive damage and possibly
affect hormone activity; therefore, we examined hormone metabolite patterns in relation to validated
smoking status. We previously conducted a prospective study of women of reproductive age
(n = 403) recruited from a large health maintenance organization, who collected urine daily during
an average of three to four menstrual cycles. Data on covariates and daily smoking habits were
obtained from a baseline interview and daily diary, and smoking status was validated by cotinine
assay. Urinary metabolite levels of estrogen and progesterone were measured daily throughout the
cycles. For the present study, we measured urinary levels of the pituitary hormone follicle-stimulating
hormone (FSH) in a subset of about 300 menstrual cycles, selected by smoking status, with the time
of transition between two cycles being of primary interest. Compared with nonsmokers, moderate to
heavy smokers (≥ 10 cigarettes/day) had baseline levels (e.g., early follicular phase) of both steroid
metabolites that were 25–35% higher, and heavy smokers (≥ 20 cigarettes/day) had lower luteal-
phase progesterone metabolite levels. The mean daily urinary FSH levels around the cycle transition
were increased at least 30–35% with moderate smoking, even after adjustment. These patterns sug-
gest that chemicals in tobacco smoke alter endocrine function, perhaps at the level of the ovary,
which in turn effects release of the pituitary hormones. This endocrine disruption likely contributes
to the reported associations of smoking with adverse reproductive outcomes, including menstrual
dysfunction, infertility, and earlier menopause. Key words: cigarette smoking, endocrine disruption,
estrogen, follicle-stimulating hormone, hormones, menstrual dysfunction, progesterone, steroids,
women’s health. Environ Health Perspect 113:1285–1290 (2005). doi:10.1289/ehp.7899 available
via http://dx.doi.org/ [Online 3 June 2005]and freeze first morning urine samples daily
for up to 6 months (Waller et al. 1998). About
half of those eligible agreed to participate, but
some later dropped out (16%) or became ineli-
gible (11%), leaving 403 women who com-
pleted urine collection. On average, women
collected urine on 92% of appropriate study
days during 5.6 menstrual cycles, but because
urine collection was not timed to the cycle start
dates, a mean of 3.6 complete cycles were col-
lected per woman. Steroid metabolites were
measured daily, and FSH was measured in a
subset of 300 cycles after additional funding
was obtained. Participants completed a detailed
baseline telephone interview that asked about
demographics, reproductive history, lifestyle
factors, and various exposures, including past
and current cigarette smoking. Women ﬁlled
out daily diaries during urine collection,
recording vaginal bleeding, intercourse, and
contraception, as well as the number of
cigarettes smoked each day.
Smoking assessment. The diary was used
for determining amount smoked because the
daily levels reported provided cycle-specific
measures. The average number of cigarettes
smoked per day for each cycle was calculated
and then categorized; for the FSH subset, we
primarily used none, low (1–9 cigarettes/day),
and moderate smoking (≥ 10 cigarettes/day).
In the full data set with larger numbers, we
also delineated a heavy smoking category
(≥ 20 cigarettes/day). To validate self-reported
smoking, pooled urine samples of 5 days from
two to three cycles of each woman were
assayed for nicotine and its metabolite coti-
nine (Elkin et al. 1999; Windham et al.
1999). All of the nonsmokers had urinary
cotinine levels < 25 ng/mL, a cut point well
within the range used in other studies
(Benowitz 1996). Two women who reported
less than daily smoking, but with measured
cotinine levels > 200 ng/mL, were excluded as
potential misreporters, as was a nonsmoker
who used nicotine gum.
Hormone end points. Steroids. The pri-
mary estradiol metabolites estrone sulfate and
estrone glucuronide [estrone conjugates (E1C)]
and the progesterone metabolite pregnanediol-
3-glucuronide (PdG) were measured daily by
enzyme-linked immunoassays and then
adjusted for creatinine concentration, as
described previously (Munro et al. 1991;
Waller et al. 1998). We determined ovulatory
status for each cycle based on a relative rise in
progesterone above baseline levels (Kassam
et al. 1996; Waller et al. 1998). The day of
ovulation (or luteal transition) was estimated
using a previously validated algorithm based on
the ratio of E1C to PdG during 5-day win-
dows where E1C was declining and PdG was
increasing (Baird et al. 1990; Waller et al.
1998; Windham et al. 2002). In a small pro-
portion (5.6%), we reassigned the day of
ovulation to better correspond to individual
steroid hormone plots. The cycle was divided
into the follicular phase (calculated from the
ﬁrst day of menses through the estimated day
of ovulation) and the subsequent luteal phase
(day after ovulation to day before next
menses). Cycle and phase lengths were catego-
rized as short and long based on the 5th and
95th percentiles of their distributions
(Windham et al. 1999). For examining and
graphing mean daily values of the steroids by
smoking status, the cycles were centered at the
estimated day of ovulation.
As noted above, urine was collected during
many partial cycles, so we generally excluded
these, as well as cycles where ≥ 30% of days of
urine were missing midcycle (~ 700 total). We
only examined steroid parameters in the
remaining 1,560 cycles for which a day of
ovulation was assigned, so we could identify
the follicular and luteal phases. Some incom-
plete ﬁrst cycles are included in the analyses of
luteal-phase measures if there was at least
20 days of urine collection and urine collec-
tion started within 14 days of the reported
last menstrual period (n = 112). Cycles with
incomplete luteal phases (which would
include successful pregnancies) were not
included in analyses of luteal-phase para-
meters, but 89 met the inclusion criteria for
follicular-phase parameters (including 39 preg-
nancies). The primary hormone parameters
calculated (Windham et al. 2002) for
1,451 follicular phases and 1,459 luteal phases
include the following:
• Baseline: the E1C baseline value calculated as
the mean over the ﬁrst 5 days of the cycle. To
avoid including elevated “spillover” proges-
terone values from the previous luteal phase
or rising levels of the next, the PdG baseline
is the minimum 5-day average occurring
before the luteal-phase 5-day maximum.
• Daily average: Mean E1C and PdG levels
calculated over the follicular phase or the
luteal phase.
• Area under the curve, or “total”: the sum of
the daily E1C values during the follicular
phase or the sum of daily PdG values during
the luteal phase.
• Peak: A 3-day average around the maximum
E1C or PdG value. For the estrogen metabo-
lite, the maximum value was selected within
a 6-day window around the day of ovulation
to capture the periovulatory peak. For prog-
esterone, the maximum value during the
luteal phase was selected. If values were miss-
ing for any of the 3 days, the peak variable
was not calculated (18–20% of cycles).
Follicle-stimulating hormone. After
procuring additional funding, cycles were
selected 2 years later for FSH assay, based on
smoking status, to reach a goal of 300 cycles in
total. Initially, all cycles of smokers (deﬁned as
an average of ≥ 1 cigarette reported/day or
cotinine > 25 ng/mL) were selected, and two
contiguous cycles of nonsmokers (cotinine
≤ 0.5 ng/mL) were randomly selected, target-
ing cycles early in urine collection to cor-
respond to the timing of a saliva sample. The
FSH assay, based on heat dissociation of the
FSH heterodimer and measurement of the
FSH β-subunit (Qiu et al. 1998), was con-
ducted blind to smoking status at the
University of California, Davis, laboratory
where it was developed. Previous studies from
the laboratory have shown good correspon-
dence between the circulating FSH hetero-
dimer and the urinary β-subunit (Li et al.
2002). The increase in FSH during the tran-
sition between menstrual cycles (e.g., luteal
phase of one cycle to follicular phase of the
next) is the initiator of events leading to ovula-
tion, so this was identiﬁed as the time period
of primary interest. FSH was measured in
daily samples from 7 days before the ﬁrst bleed
day of a cycle through 17 days afterward to
catch the periovulatory rise. Samples were run
in duplicate and the average value used, unless
the duplicates varied by > 20%, in which case
they were rerun. FSH values were also creati-
nine adjusted. For ﬁnal analyses, we used only
cycles that had adequate specimen remaining
to measure FSH during the time period of
interest. If there was inadequate sample for
nonsmokers, other cycles were substituted,
but these were not available for smokers, so
the ﬁnal sample with FSH measures included
112 menstrual cycles among 32 smokers
(9 smokers did not have sufficient urine for
FSH analyses) and 209 cycles among 93 non-
smoking comparisons.
Because there had been few prior studies
examining daily FSH levels, we calculated the
daily mean and the slope values for seven dif-
ferent 4–8 day windows of time within the
luteal–follicular transition, which were consis-
tent with earlier work from the laboratory
(De Souza et al. 1998; Qiu et al. 1997). For
FSH analyses, the ﬁrst bleed day of the cycle
was considered day 1 (with no day zero), and
we primarily report results for the following
windows: days –7 to –1, –5 to 1, –3 to 1, and
–3 to 3. For comparison with other studies
based on serum FSH, we also examined a
basal level as the mean of days 1 to 5. We also
examined the maximum FSH value midcycle
(periovulatory) and the cycle day on which it
occurred (within days 6–17). An FSH para-
meter was considered missing for a cycle if
25–30% of values within the window were
missing (e.g., > 1 day of 4-day windows or
2 days of 7-day windows). This eliminated
about 10% of sampling periods.
Statistical analysis. Numerous covariates
from the baseline interview were examined as
potential confounders, including demographics,
reproductive history, body mass index (BMI),
and other lifestyle factors (caffeine and alcohol
Windham et al.
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report, we identiﬁed variables associated with
the steroid parameters (Windham et al. 2002)
and examined these as categorical variables
(Table 1) in relation to FSH level and smok-
ing status by analysis of variance. Because the
primary analysis is at the cycle level and a
woman’s cycles are not independent observa-
tions, we used mixed models that account for
repeated measures for multivariate modeling
(Laird and Ware 1982; Zeger and Liang
1986), effectively increasing the standard
error of the estimates. Variables identiﬁed as
potential confounders were included in regres-
sion models with each covariate removed one
at a time to determine if the association
between smoking and a selected FSH parame-
ter (slope or mean of days –5 to 1) changed.
If so, that variable was included in ﬁnal multi-
variate models. Similar methods were used to
build models for examining smoking in rela-
tion to steroid levels. In ﬁnal regression mod-
els, we weighted the hormone parameters by
the proportion of nonmissing values in the
appropriate time frame during each cycle
(Windham etal. 2002). Thus, if there were
no missing values, the weight was 1, with
missing values resulting in down-weighting;
mean weights for each parameter ranged from
0.77 to 0.91.
Results
Overall, participants were predominantly
white (71%), well educated (40% had a col-
lege degree), and parous (88%), with a mean
age (± SD) of 31 ± 4.2 years (Waller et al.
1998; Windham et al. 2002). On the baseline
questionnaire, 9.2% of women reported
being current regular smokers, and the daily
diaries indicated that 10% smoked an average
of ≥ 1 cigarettes/day, with 5% smoking less
frequently. Compared with nonsmokers,
smokers were signiﬁcantly less educated, more
likely to be of a race other than Asian or
white, drank more alcoholic and caffeinated
beverages, and were more likely to have had
any pregnancy and to have had a pregnancy
loss or therapeutic abortion.
The characteristics of the FSH subset are
shown in Table 1; smokers did not vary much
from those in the overall study except they
were even less likely to have a college degree.
Nonsmokers in the subset were less likely to
be Hispanic (p = 0.04) and more likely to be
older (p = 0.10) than were all nonsmokers.
The distribution of cycle characteristics (short
cycle, long follicular phase, etc.) was similar in
the subset and the overall study, and the asso-
ciation of shorter cycle length with smoking
was also observed [crude risk ratio = 2.1; 95%
conﬁdence interval (CI), 1.1–4.0].
FSH ﬁndings. Among nonsmokers, mean
FSH levels (for days –5 to 1) tended to be
higher in nonwhite, older women with
greater caffeine consumption, and levels were
lower among women with a history of preg-
nancy loss and with greater alcohol consump-
tion (Table 1). Education, BMI, and other
reproductive history variables were not
strongly associated with FSH levels. All the
mean FSH parameters during the luteal–
follicular phase transition were significantly
inversely associated with the length of the
next cycle and follicular phase, either adjust-
ing for smoking status or among nonsmokers
only. The slope parameters that included
5–7 days of the previous cycle were also
inversely associated with cycle length.
As shown in Figure 1, the urinary FSH lev-
els reﬂect the rise during the luteal–follicular
transition, with the highest levels occurring
early in the follicular phase at days 3–5 and
then again around ovulation. Smokers tended
to have higher daily FSH levels than non-
smokers during the luteal–follicular phase
transition period. Consistent with that, mean
FSH parameters in moderate to heavy smokers
(≥ 10 cigarettes/day) compared with non-
smokers were statistically significantly
increased for all seven of the original time win-
dows (and including the early follicular-phase
mean) examined. Light smokers had levels
more similar to nonsmokers or very slightly
lower. The slopes of FSH during the corre-
sponding periods did not appear to vary con-
sistently by smoking level. Smokers did tend
to reach the midcycle peak FSH level > 1 day
earlier than did nonsmokers, with an interme-
diate value among light smokers, but this was
less strong after adjustment. One woman had
very high FSH levels, which were confirmed
on reassay; she was older, a moderate smoker,
and a heavy caffeine consumer. She was
excluded to determine the degree to which her
values were inﬂuencing results. This reduced
the mean differences between moderate smok-
ers and nonsmokers by about half, so we pre-
sent these to be conservative in Table 2
showing adjusted differences. Adjustment (for
age, race, pregnancy history, BMI, and alcohol
and caffeine consumption) changed the mag-
nitude of differences in means only very
slightly but increased the estimates for differ-
ence in slope parameters among moderate
smokers. In general, when including the
woman with the high FSH values, the mean
FSH levels during the cycle transition were
signiﬁcantly elevated by 52–57% in moderate
smokers, whereas excluding her, the means
were elevated about 30–35% (Table 2). The
Effects of cigarette smoking on hormones
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Table 1. Participant characteristics and mean FSH level in FSH subset, by smoking status.
Nonsmokers Smokers
No. of FSH No. of FSH
Variable women (%) (mean ± SD)a women (%) (mean ± SD)a
Race*
White 72 (77.4) 0.36 ± 0.17 24 (75.0) 0.50 ± 0.48
Asian 15 (16.1) 0.51 ± 0.35 2 (6.3) 0.90 ± 0.50
Other 6 (6.5) 0.48 ± 0.20 6 (18.8) 0.32 ± 0.14
Age (years)
< 30 26 (27.9) 0.33 ± 0.22 12 (37.5) 0.36 ± 0.14
30–34 34 (36.6) 0.42 ± 0.20 12 (37.5) 0.40 ± 0.21
≥ 35 33 (35.5) 0.42 ± 0.22 8 (25.0) 0.81 ± 0.74
Pregnancy history
0 pregnancies 7 (7.5) 0.49 ± 0.38 1 (3.1) 0.46 ± 0.21
≥ 1 pregnancy, 0 losses 59 (63.4) 0.41 ± 0.22 20 (62.5) 0.52 ± 0.55
≥ 1 pregnancy, ≥ 1 loss 27 (29.0) 0.34 ± 0.15 11 (34.4) 0.45 ± 0.22
Education*
No college 21 (22.6) 0.44 ± 0.23 16 (50.0) 0.55 ± 0.62
Some college 29 (31.2) 0.38 ± 0.16 13 (40.6) 0.43 ± 0.22
College graduate 43 (46.2) 0.38 ± 0.25 3 (9.4) 0.53 ± 0.14
BMI (kg/m2)
< 19.1 6 (6.5) 0.47 ± 0.44 2 (6.3) 0.29 ± 0.08
19.1–27.3 66 (71.0) 0.39 ± 0.21 19 (59.4) 0.58 ± 0.54
> 27.3 21 (22.6) 0.38 ± 0.18 11 (34.4) 0.41 ± 0.31
MET score
0 42 (45.2) 0.43 ± 0.26 10 (31.2) 0.45 ± 0.25
> 0 to < 40 37 (39.8) 0.36 ± 0.19 16 (50.0) 0.55 ± 0.63
≥ 40 14 (15.0) 0.37 ± 0.16 6 (18.8) 0.45 ± 0.21
Caffeine (mg/day)*
0 35 (37.6) 0.35 ± 0.23 3 (9.4) 0.39 ± 0.19
< 300 48 (51.6) 0.41 ± 0.21 19 (59.4) 0.44 ± 0.22
≥ 300 10 (10.8) 0.48 ± 0.21 10 (31.2) 0.63 ± 0.76
Alcohol* (drinks/week)
0 26 (28.0) 0.45 ± 0.29 5 (15.6) 0.64 ± 0.91
1–3 64 (68.8) 0.38 ± 0.19 17 (53.1) 0.41 ± 0.18
≥ 4 3 (3.2) 0.29 ± 0.09 10 (31.3) 0.55 ± 0.37
MET, metabolic equivalence.
aMean FSH for days –5 to 1 calculated for cycles (vs. woman basis). Data from Women’s Reproductive Health Study,
California Department of Health Services. *p < 0.05 for test of independence between smoking status and covariate.effect of excluding her was not consistent for
the FSH slope parameters.
Limiting the analyses to only average
length cycles (25–35 days) slightly strength-
ened the elevations in FSH associated with
moderate smoking. We examined the smok-
ing level in the previous cycle as well, that is,
the one that included the luteal phase of
interest, because this would precede FSH
measurements. A few cycles drop out because
the smoking data are missing, but results were
very similar, presumably because smoking
habits did not vary greatly across cycles.
Steroid findings. Figure 2, of daily E1C
and PdG mean levels, shows the characteristic
cyclic patterns of estrogen and progesterone
secretion. The steroid metabolites were
examined in separate models that included
age, race, education, pregnancy history, meta-
bolic equivalence (MET) score (exercise lev-
els), and caffeine consumption. The baseline
levels of both steroid hormones were elevated
among the heaviest smokers in multivariate
models, but not statistically signiﬁcantly: 22%
for E1C and nearly 40% for PdG (Table 3).
These elevations were signiﬁcant at the mod-
erate smoking cut point (≥ 10 cigarettes/day),
where there is more power; the mean baseline
E1C was elevated > 25% (β = 6.3; 95% CI,
0.40–12.3), and baseline PdG was increased
about 35% (β = 0.20; 95% CI, 0.03–0.38),
compared with nonsmokers. Progesterone
metabolite levels during the luteal phase were
somewhat lower among smokers in general
(Figure 2B) and consistently about 25% lower
among the heaviest smokers (Table 3).
Discussion
The present analysis showed that moderate to
heavy smokers had elevated baseline (e.g.,
early follicular phase) levels of the steroid
metabolites and heavy smokers had somewhat
dampened progesterone metabolite levels dur-
ing the luteal phase. Further, we found that
mean urinary FSH levels during the time of the
luteal–follicular phase transition were higher
among moderate to heavy smokers than among
nonsmokers. Combined with our previous
findings of shorter cycle and follicular-phase
lengths among heavy smokers (Windham et al.
1999), an alteration in the endocrine pattern
with smoking is indicated.
Because of the nature of its association
with various hormonally related diseases,
smoking has been considered potentially anti-
estrogenic. However, only a few studies have
provided metabolic evidence to support this,
and these studies are hampered by having few
biosampling points, a small number of sub-
jects, or inclusion of postmenopausal women.
MacMahon et al. (1982) reported reduced
urinary excretion of estrone, estradiol, and
estriol in the luteal phase among smokers,
suggesting that this may be due to reduced
estrogen production. Michnovicz et al. (1986)
found that smoking induced the 2-hydroxyla-
tion of estrone to relatively inactive metabo-
lites and decreased excretion of estriol.
However, several studies have not reported
differences in serum estradiol concentrations
with smoking in premenopausal women
(Berta et al. 1992; Key et al. 1996; Longcope
and Johnston 1988; Zumoff et al. 1990).
Some of the disease patterns observed with
smoking may actually reflect increases in
androgens or progesterone. A few studies have
reported that smoking increases adrenal activ-
ity, with elevations in adrenal androgens seen
mostly among postmenopausal smokers
(Baron et al. 1995; Friedman et al. 1987; Key
et al. 1991; Khaw et al. 1988). Zumoff et al.
(1990) measured serum levels at multiple
points during the cycle and reported elevated
serum progesterone levels during the early fol-
licular phase among smokers, when most
progesterone is of adrenocortical origin. This
is consistent with our ﬁnding of elevated base-
line progesterone levels among heavier smok-
ers. However, those authors did not report
differences in progesterone levels during the
luteal phase. Estrogen was increased in the fol-
licular phase among smokers in that study,
which we tended to observe as well. Similar to
our ﬁnding, Berta et al. (1992) found that reg-
ular moderate smokers (≥ 10 cigarettes/day for
at least 5 years) had lower plasma progesterone
levels on a single sample day during the mid-
luteal phase. With an increased baseline PdG
reﬂecting more progesterone of adrenal origin
in smokers, the decreased luteal-phase PdG
levels we observed may indicate even lower
Windham et al.
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Figure 1. Mean daily levels of urinary FSH (ng/mg creatinine) by smoking status during the luteal–follicular
phase transition. Day 1 is the ﬁrst bleed day of a cycle, or the last menstrual period (LMP); negative days
are in the previous cycle. Smokers exclude one woman with very high FSH values (see “FSH ﬁndings”);
with her included, differences would be greater and extend farther into days 7–12. Data from Women’s
Reproductive Health Study, California Department of Health Services.
Table 2. Adjustedadifference in FSH metabolic parameters by smoking level and 95% CIs.
Cigarettes/dayb
Parameter and None (n = 186) ≤ 9 (n = 49) ≥ 10 (n = 48)
cycle daysc Intercept β (95% CI) β (95% CI)
FSH slope
–7 to –1 0.02 –0.02 (–0.04 to 0.00) 0.02 (–0.003 to 0.04)
–5 to 1 0.04 –0.02 (–0.05 to 0.01) 0.02 (–0.015 to 0.06)
–3 to 1 0.09 –0.04 (–0.10 to 0.01) 0.02 (–0.04 to 0.07)
Mean daily FSH
–7 to –1 0.31 –0.03 (–0.12 to 0.06) 0.09 (–0.01 to 0.20)
–5 to 1 0.37 –0.06 (–0.17 to 0.05) 0.12 (0.00 to 0.24)
–3 to 1 0.40 –0.08 (–0.21 to 0.04) 0.14 (0.003 to 0.28)
–3 to 3 0.50 –0.08 (–0.22 to 0.06) 0.10 (–0.06 to 0.26)
1 to 5 0.68 –0.09 (–0.29 to 0.10) 0.006 (–0.22 to 0.23)
aAdjusted for age, race, pregnancy history, BMI, and alcohol and caffeine consumption in mixed models for repeated
measures, with weighting of FSH parameter by proportion of nonmissing within the window. bSmoking as reported during
cycle starting with day 1; n is for the parameter with the largest numbers. These vary by a few cycles because of missing
data; one outlier was excluded. cDays are counted with ﬁrst bleed day of a cycle numbered as day 1. Data from Women’s
Reproductive Health Study, California Department of Health Services.corpus luteum contribution of progesterone to
total excretion. Some in vitro studies (Bodis
et al. 1992; Gocze et al. 1999; Miceli et al.
2005) have found inhibition of progesterone
production by granulosa cells or luteal cells
that were treated with cigarette smoke extract
or the alkaloids found in smoke (e.g., nicotine,
cotinine, anabasine).
The serum FSH level during the first
3–4 days of the cycle is useful clinically to
assess fertility and predict success of in vitro
fertilization, as well as to identify the peri-
menopausal transition (Burger et al. 1995;
Mausher et al. 1988; Scott et al. 1989). The
few other studies that examined FSH in
relation to smoking were based on single
serum samples and included women at older
ages when FSH may be increasing peri-
menopausally. Two studies that measured
FSH at the beginning of the cycle found
higher levels associated with smoking (Cooper
et al. 1995; Cramer et al. 1994), as did a
study in which the timing of the serum draw
was not known (Backer et al. 1999). These
studies support our ﬁndings of elevated FSH
levels with smoking, but our results expand
upon them by examining the dynamics,
showing that the elevation in FSH levels
among smokers is observable at the end of the
prior luteal phase. Furthermore, we observed
this effect among reproductive-age women,
before onset of the perimenopausal transition.
There are some limitations of the present
study that should be considered. Women who
comply with the labor-intensive urine collec-
tion protocol may not be entirely generalizable,
and the eligibility criteria would tend to
exclude women with chronic menstrual cycle
disturbances. We measured estrone metabo-
lites, which may vary by woman in how well
they reﬂect serum estrogen levels. Furthermore,
we cannot establish whether secretion or
metabolism is affected by smoking. Our power
was somewhat limited for examining FSH lev-
els, because of limited funding and inadequate
remaining urine sample for some participants.
Thus, for example, we could not examine
heavier smoking levels in relation to FSH. We
did not examine the effects of passive smoking
in this study. The FSH subset should exclude
most women exposed to environmental
tobacco smoke (ETS) from nonsmokers based
on the cotinine level criteria we used
(< 0.5 ng/mL), but they would be included in
steroid hormone analyses. If ETS causes effects
in the same direction as active smoking, but
presumably to a lesser extent, this would tend
to dilute effects we observed because of ETS
exposure being included in the comparison
group. Therefore, our results may under-
estimate the magnitude of the true association
with steroid levels.
In conclusion, the present data are consis-
tent with some previously published reports
but extend them and present for the ﬁrst time
the effect of smoking on steroid and gonado-
tropin patterns across cycles. This approach
permits the evaluation of the integrity of the
HPO axis during the entire period of follicu-
lar recruitment and maturation rather than
just analyzing hormone patterns during indi-
vidual menstrual cycles. Because progesterone
modulates FSH in the endocrine feedback
loop, the lower progesterone metabolite levels
in smokers during the luteal phase are consis-
tent with decreased entrainment of FSH dur-
ing the luteal–follicular phase transition,
leading to the elevations we observed. The
shortening of the follicular phase may be a
direct consequence of the increased FSH,
consistent with other ﬁndings (Cramer et al.
1994; De Souza et al. 1998). The increase in
FSH may accelerate the recruitment and
development of follicles, moving ovulation
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Figure 2. Mean daily levels of urinary E1C (ng/mg creatinine; A) and PdG (µg/mg creatinine; B), by smoking status, in one representative cycle per participant.
Cycles are centered on the estimated day of ovulation (labeled day 0), so negative days are in the follicular phase and positive days are in the luteal phase. Data
from Women’s Reproductive Health Study, California Department of Health Services.
Table 3. Adjusteda difference and 95% CIs in steroid hormone metabolite parameters by smoking level. 
Cigarettes/day
None (nb = 1,313) ≤ 19 (n = 117) ≥ 20 (n = 25)
Hormone parameter Intercept β (95% CI) β (95% CI)
Estrogen (ng/mg creatinine)
Baseline 24.9 3.9 (0.06 to 7.6) 5.7 (–3.5 to 14.8)
Total FP 584.6 6.8 (–66.8 to 80.3) 29.1 (–159.6 to 217.8)
Daily average FP 39.0 1.2 (–3.1 to 5.5) 4.3 (–6.3 to 14.9)
Peak to periovulatory 70.4 –0.3 (–10.0 to 9.4) –11.5 (–32.7 to 9.7)
Progesterone (µg/mg creatinine)
Baseline 0.54 –0.03 (–0.14 to 0.08) 0.21 (–0.04 to 0.47)
Total LP 56.7 –1.7 (–9.4 to 5.9) –15.5 (–32.2 to 1.1)
Daily average LP 4.66 –0.17 (–0.80 to 0.47) –1.34 (–2.72 to 0.04)
Peak LP 6.64 –0.36 (–1.35 to 0.63) –1.63 (–3.65 to 0.40)
Abbreviations: FP, follicular phase; LP, luteal phase. 
aAdjusted for age, race, education, prior pregnancies, caffeine, and MET score (exercise level). bn indicates the parameter
with the largest numbers (e.g., follicular-phase estrogen and luteal-phase progesterone); others vary because of missing
data, with peaks having smaller n values by 260–300 cycles overall. Data from Women’s Reproductive Health Study,
California Department of Health Services.earlier. Short follicular phase has been associ-
ated with decreased fecundity or in vitro fer-
tilization rates in several studies (Check et al.
1992; Fukuda et al. 2001; Kolstad et al.
1999; Liss et al. 2002). Shorter follicular
phase may result in inadequate follicle devel-
opment, followed by inadequate corpus
luteum function. Because progesterone con-
trols endometrial response, it is critical for
early pregnancy maintenance; luteal-phase
deﬁciency or decreased progesterone has been
implicated as a cause of infertility and fetal
loss (Pittaway et al. 1983; Tulppala et al.
1991; Wuttke et al. 2001). This pattern of
higher FSH levels and shorter cycles in smok-
ers is also consistent with the observation that
smokers tend to experience earlier menopause
(Cooper et al. 1999; Midgette and Baron
1990). Thus, the decreased progesterone and
perturbation of FSH suggest both a target and
one mechanism by which cigarette smoke
may alter ovarian function and reduce female
fertility. Because cigarette smoke contains
thousands of chemicals, this pathway may
serve as a model for some endocrine effects of
other environmental exposures.
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